摘要
随着对胶质瘤发生发展机制的深入研究,越来越多的肿瘤标志物被用于胶质瘤的精准诊断,包括循环肿瘤细胞(CTCs)、循环肿瘤DNA(ctDNA)、微小RNA(miRNAs)、外泌体等。有别于病理组织活检,应运而生的液体活检技术,通过检测血液、脑脊液等体液中存在的特异性肿瘤标志物,不仅降低了侵入性,而且对于诊断胶质瘤,阐明肿瘤侵袭和播散的机制,揭示肿瘤异质性,设计个体化治疗和评估改善疗效意义重大。
As research in the mechanism of glioma development and progression advances,more and more tumor markers are used for the precise diagnosis of glioma,including circulating tumor cells,circulating tumor DNA,microRNA,and exosome.The newly e-merging technique,liquid biopsy,shows features differing from pathological tissue biopsy.Through detecting specific tumor markers in body fluids like blood and cerebrospinal fluid,liquid biopsy provides a less invasive but valuable way to diagnose glioma,clarify how it spreads,unravel its heterogeneity,design individualized treatment,and evaluate therapeutic effect.
作者
李峰平
李志强
LI Feng-Ping;LI Zhi-Qiang(Department of Neurosurgery,Zhongnan hospital of Wuhan University,Wuhan,Hubei 430071,China)
出处
《国际神经病学神经外科学杂志》
2020年第5期529-534,共6页
Journal of International Neurology and Neurosurgery
基金
国家自然科学基金项目(81573459)
国家卫计委医药卫生科技发展研究中心“重大疾病防治科技行动计划”:神经系统肿瘤精准诊疗技术的研发及推广应用研究(2018ZX-07S-011)。